McKesson Beats Q2 Earnings and Raises 2027 Guidance

McKesson Corporation reported second-quarter adjusted earnings per share of $11.68, surpassing analyst estimates of $10.71. Revenue increased 8% year-over-year to $111.0 billion, a growth driven by higher prescription volumes and specialty product distribution in its Oncology & Multispecialty and North American Pharmaceutical segments.

Following the results, the company raised its fiscal 2027 adjusted earnings per share guidance to a range between $45.60 and $46.40. Chair and CEO Brian Tyler attributed the performance to operational strength in core business segments and disciplined execution across the enterprise.

The company expanded its portfolio through the November 2 completion of the Precision Medicine Group acquisition. Additionally, McKesson entered a definitive agreement to invest approximately $1.4 billion for a 49% minority interest in Option Care Health, a deal currently pending regulatory and stockholder approvals. Despite the earnings beat and updated guidance, shares declined 0.8% after the announcement.